Sep 25
心脏生物科技解决方案获得加拿大卫生部MyCardia AT设备许可证
CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.
Sep 25
CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.
Sep 11
CBSC secures $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.
Sep 04
Cardiac Biotech Solutions, Inc. signs $600K exclusive distribution deal with Noventis Medical, expanding cardiac monitoring reach into Latin America.
May 08
CB Scientific, Inc. is now Cardiac Biotech Solutions, Inc., reflecting our mission to deliver advanced, cloud-connected cardiac monitoring technologies across global healthcare markets.
Feb 25
CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.
Oct 03
William “Trip” Thomas appointed Chief Financial Officer, succeeding Brooke Turk. Trip Thomas is a licensed CPA with extensive experience in financial reporting and regulatory compliance.
Aug 20
CB Scientific, Inc. announces its voluntary delisting from the OTCQB Venture Market to preserve capital for future business growth. The company’s common shares will continue trading on the OTC Pink Open Market.
Dec 14
Updates to provide device improvements while maintaining the innovative core-functionality of CBSC’s state of the art cardiac event monitor.
Dec 07
Partnership to provide high-volume manufacturing capability and facilitate obtaining requisite government approvals.
Nov 30
Agenda to include matters necessary to better position the company for anticipated growth and development.